Updated:
EyePoint
EyePoint Pharmaceuticals was founded in 2002 and originally operated under the name pSivida Corp., focusing on miniature, sustained-release drug delivery...
EyePoint
EyePoint Pharmaceuticals was founded in 2002 and originally operated under the name pSivida Corp., focusing on miniature, sustained-release drug delivery implants for chronic eye diseases. Jay S. Duker, a prominent ophthalmologist and former chair of ophthalmology at Tufts, joined as CEO in 2020 and accelerated the strategic shift toward long-acting therapies for retinal diseases. The firm's public-company structure means it operates with SEC-reporting transparency and raises capital in public equity markets rather than private fund structures. The company's platform is built around Durasert, a non-erodible intravitreal insert that delivers medication continuously over six months or longer, aiming to replace the monthly or bimonthly injections that dominate current anti-VEGF treatment for wet age-related macular degeneration and diabetic macular edema. Its lead clinical asset, EYP-1901, combines the Durasert insert with vorolanib, a tyrosine kinase inhibitor licensed from Equinox Science. Positive Phase 2 data for EYP-1901 in wet AMD was reported in December 2023, showing a treatment burden reduction exceeding 80% versus standard aflibercept injections. The firm has guided for a pivotal Phase 3 program to initiate in the second half of 2024 and has also reported Phase 2 data in non-proliferative diabetic retinopathy. EyePoint operates from Watertown, Massachusetts, a tight life-sciences cluster, and has historically partnered with major pharmaceutical companies — Alimera Sciences commercialized its earlier Iluvien implant for diabetic macular edema. As of its most recent filings, the company held approximately $330 million in cash and marketable securities following a $230 million public offering completed in December 2023, led by Jefferies, BofA Securities, and J.P. Morgan. December 2023: EyePoint reported positive topline data from its Phase 2 DAVIO 2 trial of EYP-1901 in wet AMD, with the treatment arm maintaining vision and anatomical control while eliminating over 80% of required supplemental injections through 56 weeks. The genuine structural difference driving EyePoint's profile is its purely public-equity-funded, single-platform clinical model operating in a sector dominated either by private venture-backed startups or big-cap pharmaceutical balance sheets. This positions it as a publicly tradable proxy for sustained-release ophthalmology innovation, making it unusually accessible to institutional health-care crossover funds and biotech event-driven allocators who require SEC-audited trial reads, rather than relying on private company board reporting.
General information
Firm type
Asset Manager
Year founded
2002
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Watertown
Corporate office
Watertown, MA, United States
Principals
Jay S. Duker
Chief Executive Officer
Sector focus
Frequently asked questions
Who runs investment decisions at EyePoint?
EyePoint is an operating public biotechnology company, not an investment firm. Strategic and capital allocation decisions are made by CEO Jay S. Duker and the board of directors, with clinical portfolio direction driven by the company's internal R&D and business development teams. Capital markets decisions are shaped by the company's need to fund Phase 3 trials and pre-commercialization activities through public offerings or partnership revenue.
What is the clinical mechanism behind EyePoint's lead asset?
EYP-1901 pairs the firm's proprietary Durasert non-erodible intravitreal insert with vorolanib, a tyrosine kinase inhibitor that blocks VEGF receptors and other angiogenic pathways. The insert is injected into the eye and releases the drug continuously over six to nine months, replacing the monthly or bimonthly intravitreal injections required by standard anti-VEGF biologics like aflibercept or ranibizumab. The Phase 2 DAVIO 2 trial demonstrated that this approach reduced supplemental injection burden by more than 80% while maintaining visual acuity outcomes.
Does EyePoint own the Durasert platform outright?
Yes, Durasert is EyePoint's wholly owned, proprietary delivery platform. The company has built in-house manufacturing capabilities at its facilities and holds extensive patent protection around the insert design and its combinations with specific active pharmaceutical ingredients. Vorolanib, the drug payload for EYP-1901, is licensed from Equinox Science, a Bay Area biotech.
How does EyePoint fund its operations?
EyePoint is a publicly traded company on NASDAQ and funds its clinical programs primarily through public equity offerings. In December 2023, it raised approximately $230 million in a follow-on offering. Prior to the strategic pivot, legacy commercial revenue came from its Yutiq and Dexycu implant products, though the company sold Yutiq rights to Alimera in 2023 to focus entirely on its pipeline programs.
Who are EyePoint's main competitors?
In the wet AMD space, EyePoint competes indirectly with the dominant anti-VEGF biologic franchises from Regeneron (aflibercept/Eylea) and Roche/Genentech (ranibizumab/Lucentis, faricimab/Vabysmo). Other sustained-release approaches in development include Roche's Susvimo port delivery system and Ocular Therapeutix's hydrogel-based Axpaxli. The firm is also observed against gene-therapy approaches aiming for a one-time treatment, though those target a different risk profile and clinical timeline.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: